New hemophilia treatment approved

Key, Nigel
March 2008
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p9
The article reports on the U.S. Food & Drug Administration approval of Wyeth Pharmaceuticals' Xyntha, a recombinant factor VIII for the treatment of hemophilia A for the control and prevention of bleeding episodes and surgical prophylaxis. It was genetically engineered from the genes of Chinese Hamster Ovary cells.


Related Articles

  • FDA Licenses New Hemophilia Treatment.  // Pharmaceutical Processing;Mar2008, Vol. 23 Issue 3, p82 

    The article reports on the approval of the Food and Drug Administration (FDA) on Xyntha Antihemophilic Factor Plasma/Albumin Free for treatment of hemophilia A, manufactured by Wyeth Pharmaceuticals Inc. in the U.S. Xyntha controls and prevents bleeding which occurs during or after an accident,...

  • FDA approves Enbrel to treat psoriasis.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p13 

    Reports on the approval given to Enbrel, the rheumatoid arthritis drug marketed by Amgen Inc. and Wyeth Pharmaceuticals, by the U.S. Food and Drug Administration for the treatment of adult patients with chronic, moderate to severe plague psoriasis. Treatment options for psoriasis; Dosage of the...

  • Additional antihemophilic factor to be available. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;4/1/2008, Vol. 65 Issue 7, p592 

    The article reports that Wyeth Pharmaceuticals Inc. has received an approval from the U.S. Food and Drug Administration (FDA) to manufacture Xyntha, a recombinant antihemophilic factor produced without plasma and albumin. It is expected that the product will be introduced in the U.S. by the...

  • NEW DELIVERY.  // Drug Topics;10/25/2004, Vol. 148 Issue 20, p50 

    This article reports that Wyeth Pharmaceuticals has the U.S. Food and Drug Administration approval for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit. This is the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia. ReFacto is indicated for the control...

  • Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Goodsaid, Federico M.; Amur, Shashi; Aubrecht, Jiri; Burczynski, Michael E.; Carl, Kevin; Catalano, Jennifer; Charlab, Rosane; Close, Sandra; Cornu-Artis, Catherine; Essioux, Laurent; Fornace, Albert J.; Hinman, Lois; Huixiao Hong; Hunt, Ian; Jacobson-Kram, David; Jawaid, Ansar; Laurie, David; Lesko, Lawrence; Heng-Hong Li; Lindpaintner, Klaus // Nature Reviews Drug Discovery;Jun2010, Vol. 9 Issue 6, p435 

    Heterogeneity in the underlying mechanisms of disease processes and inter-patient variability in drug responses are major challenges in drug development. To address these challenges, biomarker strategies based on a range of platforms, such as microarray gene-expression technologies, are...

  • Decisions Update.  // PharmaWatch: Biotechnology;Sep2006, Vol. 5 Issue 9, p17 

    The article reports developments on the drug applications of several pharmaceutical companies to the U.S. Food and Drugs Administration (FDA) in 2006. The FDA has granted fast track status to Wyeth Pharmaceuticals and Progenics Pharmaceuticals Inc.'s intravenous form of methylnaltrexone being...

  • Wyeth Pharmaceuticals, Inc.; Withdrawal of Approval of a New Drug Application for DURACT Capsules. Woodcock, Janet // Federal Register (National Archives & Records Service, Office of;7/9/2012, Vol. 77 Issue 131, p40367 

    The article presents a notice from the U.S. Food and Drug Administration (FDA) on its withdrawal of the approval of a drug application of Wyeth Pharmaceuticals Inc. for DURACT Capsules as requested by Wyeth.

  • ReFacto Lessens The Risk Of Viral Transmission.  // RN;Sep2000, Vol. 63 Issue 9, p118 

    Informs on the United States Food and Drug Administration's approval of ReFacto for the control and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency). Less risk of viral transmission.

  • Alprolix approved for hemophilia B.  // Hem/Onc Today;5/10/2014, Vol. 15 Issue 9, p25 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved Alprolix, the first long-acting recombinant coagulation factor IX indicated for patients with hemophilia B, as of May 2014.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics